267 related articles for article (PubMed ID: 27292261)
1. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
da Motta LL; Ledaki I; Purshouse K; Haider S; De Bastiani MA; Baban D; Morotti M; Steers G; Wigfield S; Bridges E; Li JL; Knapp S; Ebner D; Klamt F; Harris AL; McIntyre A
Oncogene; 2017 Jan; 36(1):122-132. PubMed ID: 27292261
[TBL] [Abstract][Full Text] [Related]
2. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
3. Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer.
Mustafi S; Camarena V; Qureshi R; Yoon H; Volmar CH; Huff TC; Sant DW; Zheng L; Brothers SP; Wahlestedt C; Slingerland J; Wang G
EBioMedicine; 2019 May; 43():201-210. PubMed ID: 30975544
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
[TBL] [Abstract][Full Text] [Related]
5. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
6. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
7. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
8. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Nieto-Jimenez C; Galan-Moya EM; Corrales-Sanchez V; Noblejas-Lopez MDM; Burgos M; Domingo B; Montero JC; Gomez-Juarez M; Picazo-Martinez MG; Esparis-Ogando A; Pandiella A; Ocaña A
Cancer Lett; 2020 Oct; 491():50-59. PubMed ID: 32735909
[TBL] [Abstract][Full Text] [Related]
10. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
11. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.
Bid HK; Phelps DA; Xaio L; Guttridge DC; Lin J; London C; Baker LH; Mo X; Houghton PJ
Mol Cancer Ther; 2016 May; 15(5):1018-28. PubMed ID: 26908627
[TBL] [Abstract][Full Text] [Related]
12. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
13. Para-toluenesulfonamide, a novel potent carbonic anhydrase inhibitor, improves hypoxia-induced metastatic breast cancer cell viability and prevents resistance to αPD-1 therapy in triple-negative breast cancer.
Chen HY; Lin CE; Wu SC; Yang ZY; Chiang YF; Huang KC; Wang KL; Ali M; Shieh TM; Chang HY; Huang TC; Hsia SM
Biomed Pharmacother; 2023 Nov; 167():115533. PubMed ID: 37748406
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
Yellapu NK; Ly T; Sardiu ME; Pei D; Welch DR; Thompson JA; Koestler DC
BMC Cancer; 2022 Jun; 22(1):627. PubMed ID: 35672711
[TBL] [Abstract][Full Text] [Related]
15. Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models.
Logsdon DP; Grimard M; Luo M; Shahda S; Jiang Y; Tong Y; Yu Z; Zyromski N; Schipani E; Carta F; Supuran CT; Korc M; Ivan M; Kelley MR; Fishel ML
Mol Cancer Ther; 2016 Nov; 15(11):2722-2732. PubMed ID: 27535970
[TBL] [Abstract][Full Text] [Related]
16. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone downregulates expression of carbonic anhydrase IX via HIF-1α and NF-κB-dependent mechanisms.
Simko V; Takacova M; Debreova M; Laposova K; Ondriskova-Panisova E; Pastorekova S; Csaderova L; Pastorek J
Int J Oncol; 2016 Oct; 49(4):1277-88. PubMed ID: 27431580
[TBL] [Abstract][Full Text] [Related]
18. BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells.
Rossi T; Zamponi R; Chirico M; Pisanu ME; Iorio E; Torricelli F; Gugnoni M; Ciarrocchi A; Pistoni M
J Exp Clin Cancer Res; 2023 Jan; 42(1):7. PubMed ID: 36604676
[TBL] [Abstract][Full Text] [Related]
19. ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis.
Wang L; Chen Y; Mi Y; Qiao J; Jin H; Li J; Lu Z; Wang Q; Zou Z
Biochem Biophys Res Commun; 2021 Jun; 558():216-223. PubMed ID: 33008584
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer.
Ong CHC; Lee DY; Lee B; Li H; Lim JCT; Lim JX; Yeong JPS; Lau HY; Thike AA; Tan PH; Iqbal J
Breast Cancer Res; 2022 Jun; 24(1):38. PubMed ID: 35659359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]